Ardelyx, Inc. (ARDX)

NASDAQ • Healthcare

$3.58

-$0.04 (-1.1%)

Market closed

Last close at September 11, 2026 at 20:00 UTC

Open$3.65

Day Range$3.56 - $3.68

Avg. Volume (3M)3.7M

Market Cap$884.3M

52 Week Range

$3.56$8.4

Next EarningsIn 46 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$120.8M100%

Gross Profitminus cost of goods$115.1M95%

In plain terms: out of every $100 in revenue, Ardelyx, Inc. currently loses $14.

Fundamentals & Financials

Revenue (TTM)

$450.8M

Net Income (TTM)

-$55.7M

EPS (TTM)

-$0.23

ROA (TTM)

-9.67%

Current Ratio

3.34

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+38.5%Q3 2025-$0.08

+93.3%Q4 2025$0

0.0%Q1 2026$0.02

-15.4%Q2 2026-$0.15

-7.0%Q3 2026-$0.07

Oct 29

in 46 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -7.0%

Ardelyx missed consensus on both the top and bottom line in the second fiscal quarter of 2026, reported Aug. 6 based on preliminary results, as EPS of -$0.07 versus the -$0.07 estimate was marked down 7.0% and revenue of about $120.9 million came in 0.1% below the $121.0 million consensus. Revenue rose 23.8% from $97.7 million a year ago, with gross profit around $115.1 million and gross margin near 95%, while operating loss reached about $12.4 million on an operating margin of -10.3%. Net income was a loss of about $16.7 million, up 12.4% from a loss of $19.1 million a year ago, and operating cash flow was negative $38.6 million.

View full earnings history

About Ardelyx, Inc.

Ardelyx, Inc. is a NASDAQ-listed biotechnology company focused on gastrointestinal and cardiorenal conditions, with tenapanor as its marketed product and pipeline anchor. The company generated $407.3 million of revenue in FY2025. Ardelyx changed its name from Nteryx, Inc. and operates from Waltham, Massachusetts.

Name

Ardelyx, Inc.

CEO

Michael G. Raab

Website

www.ardelyx.com

Industry

Healthcare

Year Founded

2007

Employees

489

Today's Snapshot

AI-generated

ARDX closed 1.1% below yesterday's close, while its sector was flat. Volume was about half as much again as its usual level.

Trading Volume

Above 10d avg 4.0M

5.6M

vs S&P 500 Today

Underperforming Market

-2.03%

Updated: September 11, 2026 at 20:32 UTC

Technical Indicators

2 Buy1 Neutral5 Sell

ARDX exhibits a pronounced bearish profile with multiple confirms of a dominant downtrend. ADX is very high, signaling a strong trend, while price sits well below short, medium and long-term moving averages, showing persistent downside placement. Momentum and CCI readings are negative despite oversold oscillators hinting at relief, and on-balance volume is deeply negative, indicating sustained distribution. ATR is moderate relative to price, and the pivot sits just above the market. Technical takeaway: Strong sell bias dominated by a powerful downtrend and heavy selling volume.

All signals